Anticancer Chemosensitization and Radiosensitization by the Novel Poly(ADP-ribose) Polymerase-1 Inhibitor AG14361

2004483 citationsJournal Articlebronze Open Access

Authors

Christopher Calabrese · Newcastle University

Robert J. Almassy

Abstract

AG14361 is, to our knowledge, the first high-potency PARP-1 inhibitor with the specificity and in vivo activity to enhance chemotherapy and radiation therapy of human cancer.

Topics & Keywords

PARP inhibition in cancer therapy DNA Repair Mechanisms Integrated Circuits and Semiconductor Failure Analysis

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: JNCI Journal of the National Cancer Institute

Volume 96, Issue 1, pp. 56-67

DOI: 10.1093/jnci/djh005

Field-Weighted Citation Impact: 10.63